Xvivo Perfusion AB (publ) (XVIPF)
XVIPF Stock Price Chart
Explore Xvivo Perfusion AB (publ) interactive price chart. Choose custom timeframes to analyze XVIPF price movements and trends.
XVIPF Company Profile
Discover essential business fundamentals and corporate details for Xvivo Perfusion AB (publ) (XVIPF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
21 Jul 2014
Employees
193.00
Website
https://www.xvivoperfusion.comCEO
Christoffer Rosenblad
Description
Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.
XVIPF Financial Timeline
Browse a chronological timeline of Xvivo Perfusion AB (publ) corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 22 Apr 2026
Upcoming earnings on 26 Jan 2026
Upcoming earnings on 22 Oct 2025
Earnings released on 11 Jul 2025
EPS came in at $0.01 falling short of the estimated $0.06 by -91.98%, while revenue for the quarter reached $18.63M , missing expectations by -90.86%.
Earnings released on 24 Apr 2025
EPS came in at -$0.04 falling short of the estimated $0.08 by -150.23%, while revenue for the quarter reached $21.84M , missing expectations by -89.80%.
Earnings released on 28 Jan 2025
EPS came in at $0.10 falling short of the estimated $0.12 by -16.93%, while revenue for the quarter reached $20.48M , missing expectations by -91.94%.
Earnings released on 24 Oct 2024
EPS came in at $0.26 surpassing the estimated $0.08 by +221.31%, while revenue for the quarter reached $19.13M , missing expectations by -5.14%.
Earnings released on 12 Jul 2024
EPS came in at $0.08 surpassing the estimated $0.06 by +35.68%, while revenue for the quarter reached $19.90M , beating expectations by +9.42%.
Earnings released on 24 Apr 2024
EPS came in at $0.07 surpassing the estimated $0.04 by +81.91%, while revenue for the quarter reached $17.15M , beating expectations by +10.03%.
Earnings released on 25 Jan 2024
EPS came in at $0.22 surpassing the estimated $0.05 by +365.47%, while revenue for the quarter reached $15.40M , missing expectations by -9.97%.
Earnings released on 30 Sept 2023
EPS came in at $0.01 falling short of the estimated $0.04 by -82.58%, while revenue for the quarter reached $13.31M , missing expectations by -6.69%.
Earnings released on 30 Jun 2023
EPS came in at $0.02 falling short of the estimated $0.03 by -34.58%, while revenue for the quarter reached $14.25M , beating expectations by +5.70%.
Earnings released on 31 Mar 2023
EPS came in at $0.05 surpassing the estimated $0.03 by +36.83%, while revenue for the quarter reached $13.51M , beating expectations by +8.82%.
Earnings released on 26 Jan 2023
EPS came in at $0.27 falling short of the estimated $0.48 by -43.75%, while revenue for the quarter reached $12.84M , beating expectations by +14.87%.
Earnings released on 27 Oct 2022
EPS came in at $0.32 surpassing the estimated $0.20 by +60.00%, while revenue for the quarter reached $8.64M , beating expectations by +3.54%.
Earnings released on 13 Jul 2022
EPS came in at $0.15 falling short of the estimated $0.20 by -25.00%, while revenue for the quarter reached $9.17M , missing expectations by -0.23%.
Earnings released on 25 Apr 2022
EPS came in at $0.14 falling short of the estimated $0.16 by -12.50%, while revenue for the quarter reached $9.88M , beating expectations by +64.71%.
Earnings released on 27 Jan 2022
EPS came in at $0.74 surpassing the estimated $0.05 by +1.38K%, while revenue for the quarter reached $9.46M , beating expectations by +7.82%.
Earnings released on 21 Oct 2021
EPS came in at -$0.04 falling short of the estimated -$0.03 by -33.33%, while revenue for the quarter reached $6.26M .
Earnings released on 13 Jul 2021
EPS came in at -$0.31 falling short of the estimated $0.19 by -263.16%, while revenue for the quarter reached $6.91M .
Earnings released on 21 Apr 2021
EPS came in at $0.02 , while revenue for the quarter reached $6.67M .
Earnings released on 28 Jan 2021
EPS came in at -$0.21 falling short of the estimated $0.19 by -210.53%, while revenue for the quarter reached $7.32M .
Earnings released on 23 Oct 2020
EPS came in at $0.20 surpassing the estimated $0.15 by +33.33%, while revenue for the quarter reached $4.78M , missing expectations by -15.22%.
XVIPF Stock Performance
Access detailed XVIPF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.